Surfaxin Approval History 
- FDA approved: Yes (First approved March 6th, 2012)
- Brand name: Surfaxin
- Generic name: lucinactant
- Company: Discovery Laboratories, Inc.
- Treatment for: Respiratory Distress Syndrome
Surfaxin (lucinactant) is a synthetic, peptide-containing surfactant indicated for the prevention of respiratory distress syndrome (RDS) in premature infants.
FDA Approval History for Surfaxin
| Date | Article |
|---|
| Mar 6, 2012 |  Discovery Labs Announces FDA Approval of Surfaxin (lucinactant) for Prevention of Respiratory Distress Syndrome |
| Oct 12, 2011 | Discovery Labs Notified of PDUFA Date for Surfaxin |
| Sep 6, 2011 | Discovery Labs Submits Surfaxin Complete Response to FDA |
| Feb 1, 2011 | Discovery Labs Provides Expanded Update Regarding Its Program for Surfaxin U.S. Marketing Authorization |
| Jan 10, 2011 | Discovery Labs Provides Update Regarding Its Program for Surfaxin U.S. Marketing Authorization |
| Jun 8, 2010 | Discovery Labs Receives FDA Guidance Regarding Preclinical Program to Gain Surfaxin Approval |
| May 19, 2010 | Discovery Labs Achieves Key Milestone Towards Potential Surfaxin Approval |
| Oct 2, 2009 | Discovery Labs and FDA Establish Path for Potential Surfaxin Approval |
| Sep 11, 2009 | Discovery Labs and FDA to Meet On September 29, 2009 to Discuss Potential Path for Surfaxin Approval |
| Jul 2, 2009 | Discovery Labs Reports On Surfaxin End of Review Meeting With FDA |
| May 12, 2009 | Discovery Labs and FDA to Meet On June 2, 2009 to Discuss Surfaxin Complete Response Letter |
| Nov 10, 2008 | FDA Establishes Target Action Date of April 17, 2009 for Potential Approval of Discovery Labs' Surfaxin |
| Oct 20, 2008 | Discovery Labs Submits Complete Response to May 2008 FDA Approvable Letter for Surfaxin for RDS |
| Sep 24, 2008 | Discovery Labs Reports Technical Achievements Towards Gaining FDA Approval of Surfaxin |
| Aug 6, 2008 | Discovery Labs Reports Progress in Responding to Surfaxin FDA Approvable Letter |
| Jun 19, 2008 | Discovery Labs and FDA Meet to Clarify Limited Items in Surfaxin
Approvable Letter |
| May 29, 2008 | Discovery Labs and FDA to Meet On June 18, 2008 to Clarify Limited
Items in Surfaxin Approvable Letter |
| May 5, 2008 | Discovery Labs Provides Guidance On FDA Approvable Letter for
Surfaxin for RDS |
| May 2, 2008 | Discovery Labs Receives An Approvable Letter From FDA for Surfaxin
for RDS |
| Nov 16, 2007 | Discovery Labs' Response to Surfaxin Approvable Letter Deemed
Complete by FDA |
| Nov 1, 2007 | Discovery Labs Submits Response to FDA Approvable Letter for
Surfaxin for RDS in Premature Infants |
| Oct 1, 2007 | Surfaxin Process Validation Batches Achieve Stability Milestone to
Enable Filing of Response to FDA Approvable Letter |
| Aug 2, 2007 | Discovery Labs Provides Update On Progress for Surfaxin for RDS |
| Jan 22, 2007 | Discovery Labs and FDA Reach Clarity On Path Towards Surfaxin RDS Approval |
| Sep 28, 2006 | Discovery Labs Updates Progress On Manufacturing Remediation and Surfaxin FDA Regulatory Matters |
| Apr 5, 2006 | Discovery Labs Receives Second Approvable Letter From FDA for Surfaxin for RDS |
| Oct 21, 2005 | FDA Accepts Discovery Labs' Complete Response to Approvable Letter for Surfaxin |
| Aug 19, 2005 | Discovery Labs Provides Update on Status of Response to FDA Approvable Letter for Surfaxin |
| Aug 15, 2005 | Discovery Labs Provides Status of Previously Submitted Response to FDA Approvable Letter for Surfaxin |
| Jul 29, 2005 | Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin for RDS in Premature Infants |
| Feb 14, 2005 | Discovery Labs Receives Approvable Letter from FDA for Surfaxin for Respiratory Distress Syndrome in Premature Infants |
| Jun 15, 2004 | Discovery Laboratories Announces FDA Acceptance of Surfaxin New Drug Application |
| Apr 14, 2004 | Discovery Laboratories Files New Drug Application with the FDA to Market Surfaxin for the Prevention of Respiratory Distress Syndrome in Premature Infants |
See also...
Surfaxin (lucinactant) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
